How to identify pathogens when blood culture is negative?

Annually, 15.000  patients in the Netherlands only are tested for blood stream infections and almost 100 of these patients die weekly  because of these blood stream infections (sepsis). Each hour that the sepsis treatment is delayed, the mortality risk increases with nearly 8%. Because of this, fast determination is essential for the treatment of sepsis infections. But, up to 50% of these infections are not detected by blood culture determination! Aside from the fact that blood culture determination is really slow as well. Results are obtained within 3-7 days. The faster a pathogen can be determined, the faster a fitting treatment can start.

Molzym created a technology that is designed to rapidly detect over 1300 bacterial and fungal pathogens. Molzym SepsiTest™-UMD allows the diagnose of true infections by identifying pathogens in blood culture negative patients. This increases the positivity rate with 40-67%. The capacity to identify pathogens of this method is twice as high as blood culture. The SepsiTest™-UMD is a molecular diagnostics method that gives results in less than 10 hours, and thus saving 80% time to the gold standard. Another positive side to this method is, that no sub-culturing is needed for accurate results. When a pathogen is detected by blood culture, it does not mean that the pathogen is strain specific determined. With the SepsiTest™-UMD, a direct identification can be done because the processing line describes a sanger sequencing analysis after a pathogen is found by the 16S & 18S Real-Time PCR. This results in a specific identification of the pathogen. More than 1300 different pathogens have been identified with Molzyms method, until now.

We can help you reduce the sepsis mortality rate with this product. 

Click here for more information about the Molzym product line. And here you can find our contact form if you want to receive more specific information.

Share on facebook
Share on email
Share on linkedin

Copyright © 2020 Goffin Molecular Technologies